Evidence map›Paper›PMID 33917469›Full record

ReviewCancers2021

Plasma-Treated Solutions (PTS) in Cancer Therapy.

Hiromasa Tanaka, Sander Bekeschus, Dayun Yan, Masaru Hori, Michael Keidar, Mounir Laroussi

Registry-linked trialAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05924867 (Application of Plasma Activated Saline in Wound Treatment), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05924867 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Application of Plasma Activated Saline in Wound Treatment

TypeinterventionalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2023 to 2024Enrolled162ConditionsWound, Wound Infection, Wound HealArmsplasma activated saline, Routine nursing
3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Medical Gas Plasma Inactivates Adenoviruses via Capsid Oxidation.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hiromasa TanakaCenter for Low-Temperature Plasma Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan.ORCID 0000-0003-0105-6017
Sander BekeschusZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.ORCID 0000-0002-8773-8862
Dayun YanDepartment of Mechanical and Aerospace Engineering, The George Washington University, Washington, DC 20052, USA.ORCID 0000-0002-9801-021X
Masaru HoriCenter for Low-Temperature Plasma Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan.
Michael KeidarDepartment of Mechanical and Aerospace Engineering, The George Washington University, Washington, DC 20052, USA.
Mounir LaroussiPlasma Engineering and Medicine Institute, Old Dominion University, Norfolk, VA 23508, USA.ORCID 0000-0001-6871-9001

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cold physical plasma is a partially ionized gas generating various reactive oxygen and nitrogen species (ROS/RNS) simultaneously. ROS/RNS have therapeutic effects when applied to cells and tissues either directly from the plasma or via exposure to solutions that have been treated beforehand using plasma processes. This review addresses the challenges and opportunities of plasma-treated solutions (PTSs) for cancer treatment. These PTSs include plasma-treated cell culture media in experimental research as well as clinically approved solutions such as saline and Ringer's lactate, which, in principle, already qualify for testing in therapeutic settings. Several types of cancers were found to succumb to the toxic action of PTSs, suggesting a broad mechanism of action based on the tumor-toxic activity of ROS/RNS stored in these solutions. Moreover, it is indicated that the PTS has immuno-stimulatory properties. Two different routes of application are currently envisaged in the clinical setting. One is direct injection into the bulk tumor, and the other is lavage in patients suffering from peritoneal carcinomatosis adjuvant to standard chemotherapy. While many promising results have been achieved so far, several obstacles, such as the standardized generation of large volumes of sterile PTS, remain to be addressed.

Indexed as

cold physical plasmalow-temperature plasmanonthermal plasmaoncologyPAMplasma-activated mediumplasma medicinereactive nitrogen speciesreactive oxygen species

Identifiers

PMID33917469
PMCPMC8038720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.